Visacor

País: Nova Zelândia

Língua: inglês

Origem: Medsafe (Medicines Safety Authority)

Ingredientes ativos:

Rosuvastatin calcium 20.8mg equivalent to 20 mg rosuvastatin;  

Disponível em:

AstraZeneca Limited

DCI (Denominação Comum Internacional):

Rosuvastatin calcium 20.8 mg (= 20 mg rosuvastatin)

Dosagem:

20 mg

Forma farmacêutica:

Film coated tablet

Composição:

Active: Rosuvastatin calcium 20.8mg equivalent to 20 mg rosuvastatin   Excipient: Calcium phosphate Crospovidone Hypromellose as Opadry Pink Iron oxide red as Opadry Pink Lactose monohydrate as Opadry Pink   Magnesium stearate Microcrystalline cellulose Titanium dioxide as Opadry Pink Triacetin as Opadry Pink

Unidades em pacote:

Blister pack, Al/Al foil, 30 tablets

Classe:

Prescription

Tipo de prescrição:

Prescription

Fabricado por:

AstraZeneca UK Ltd

Indicações terapêuticas:

VISACOR is indicated to: - Reduce elevated LDL-C, Total Cholesterol, triglycerides and to increase HDLcholesterol in patients with primary hypercholesterolemia (heterozygous familial and non familial) and mixed dyslipidaemia (Fredrickson Types IIa and IIb). - Treat isolated hypertriglyceridaemia (Fredrickson Type IV hyperlipidaemia). Reduce Total Cholesterol and LDL-C in patients with homozygous familial hypercholesterolemia, as an adjunct to diet and other lipid lowering treatments (eg. LDL apheresis) or alone if such treatments are unavailable.

Resumo do produto:

Package - Contents - Shelf Life: Blister pack, Al/Al foil - 30 tablets - 36 months from date of manufacture stored at or below 30°C

Data de autorização:

2009-07-31